Anti-Aging & Firming Skincare OEM: Peptide Quote Guide
Illustrative concentration comparison, not a recommended formula or a specification for any named ingredient. The proportions shown are schematic.
Ask three factories for an anti-aging skincare OEM quote on a 3% peptide serum and the proposals may describe different products. One may mean 3% of a supplier's peptide solution; another may mean 3% of an in-house blend. Neither figure tells you the pure peptide content without the material specification.
This matters when comparing a peptide serum, a firming cream and a targeted patch. The percentage in the quotation, the claim on the label and the finished format need to describe the same product. A larger number alone does not establish better wrinkle or firmness results.
This guide keeps those three decisions together: identify the raw material and concentration basis, define the intended cosmetic claim and market, then verify the proposed serum, cream or patch in its final packaging.
Why the Same "3% Peptide" Can Describe Different Products
Many cosmetic peptide ingredients are supplied as blends containing carriers as well as peptides. For example, Croda's Matrixyl 3000 ingredient page lists glycerin, water and other components alongside Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7. It also distinguishes several grades, including an oil-soluble version. A brand name alone therefore does not fully identify the material being quoted.
So "3%" can mean:
- 3% of the supplied material: 3 kg of that commercial ingredient in a 100 kg batch, including its carriers.
- 3% pure peptide: 3 kg of the specified peptide itself in that batch. This is a different specification, not another way to describe the first one.
- 3% of a factory blend: the total addition of a blend whose composition must be disclosed to the appropriate technical reviewer before its peptide contribution can be compared.
A worked example: suppose an unnamed supplier solution contains 0.05% of one peptide by weight. Adding 3% of that solution gives 3 × 0.05 ÷ 100 = 0.0015% peptide, or 15 ppm, in the total formula. In a 100 kg batch, that is 3 kg of solution containing 1.5 g of peptide. These are hypothetical numbers for explaining the calculation; they are not the assay of Matrixyl, Argireline or any product offered here, and they are not a formulation recommendation.
The calculation describes the theoretical input. It does not measure how much remains after manufacture or storage, how much reaches the intended site, or the result on skin. For several peptides in one blend, calculate each separately from its documented content. If that information is unavailable, record the pure-peptide level as unconfirmed rather than deriving it from the INCI list.
This is why a quotation should state the manufacturer, exact grade, inclusion level and basis explicitly. Compare the same specification before comparing price. The same discipline applies to how formulation cost is built up: changing a supplied solution can change the carrier system and supporting formulation work as well as the active cost.
Read Ingredient Levels as Specifications, Not Universal Tiers
A supplier's recommended use level, the concentration used in a study, a safety assessment and a legal restriction answer different questions. A reported use level is not automatically a legal maximum; a recommended addition is not proof that every finished product at that level will deliver the supplier's study result.
On a small screen, swipe the table horizontally to read all columns.
| Ingredient direction | What the percentage must identify | What to request before approval |
|---|---|---|
| Matrixyl 3000 | Exact supplier grade and percentage of the material as supplied; peptide content is a separate figure. | Current technical data, composition and the relevant study formulation. Compare these with the proposed peptide serum, rather than treating every Matrixyl grade as interchangeable. |
| Argireline / Acetyl Hexapeptide-8 | Exact commercial product, such as the named peptide solution, rather than a percentage attached only to the peptide family. | Supplier identity, grade, composition and use instructions. Lubrizol lists Argireline peptide solution C as a specific product. Do not infer equivalence with another peptide from equal addition percentages. |
| Adenosine | Material purity or solution strength, and the resulting adenosine level in the finished formula. | Market-specific ingredient and claim review, relevant evidence and formula compatibility. Do not treat a concentration quoted for one regulatory route as a worldwide efficacy threshold or ceiling. |
| Caffeine | Whether the number describes pure caffeine, a supplied blend, the patch liquid or the complete patch. | Solubility and crystallisation observations in the proposed system, pack stability and evidence for the intended appearance claim. A cream and a patch need separate specifications. |
| Niacinamide | Raw-material grade and finished-formula level, including any contribution from blends. | Review the whole formula, pH, processing, stability, intended use and tolerability. Decide proposed combinations with acids, retinoids or vitamin C through formulation and safety review; a concentration headline alone cannot settle compatibility. |
For buyers, the useful comparison is not "which ingredient has the highest hero tier?" It is whether the quotation identifies the material well enough to reproduce the agreed sample and judge the evidence. Ask to see the current supplier document behind any proposed level when you verify a factory's formulation capability.
The Adenosine Case: Check the Market Before Choosing a Number
If a supplier recommends 0.04% adenosine for a particular destination, ask which current rule, claim pathway or study supports that recommendation. Establish whether the figure is a condition of a specific route, a tested concentration or an internal formulation choice. These are different reasons for selecting the same number.
This guide does not use 0.04% as a universal anti-wrinkle threshold, or convert concentrations reported in a use survey into face and body limits. For a China or Korea brief, have the proposed claim, ingredient identity, concentration and applicable submission requirements checked for that market before fixing the formula. Raising or lowering adenosine alone does not demonstrate compliance or a stronger finished-product result.
Claim Classification Decides the Evidence You Need
Write the intended claim early enough to shape the test plan. A temporary hydrated appearance after using a patch is a different endpoint from a visible change assessed after repeated use of a serum. Neither can be established simply by matching a raw-material percentage.
- For the United States, distinguish appearance from structure or function. FDA explains that making lines less noticeable through moisturisation can be cosmetic, while claims to increase collagen production or remove wrinkles can make a product a drug or medical device. Review the whole presentation, not just an added word such as "appearance". See FDA's anti-aging product guidance.
- For EU claims, connect the evidence to the product. The EU common criteria for cosmetic claims require adequate, verifiable support and caution against attributing an ingredient's properties to a finished product without a basis. A supplier study helps assess a proposal; it is not automatically your product's claim evidence.
- For firming patches and creams, define what will be observed. A targeted face-patch brief should distinguish fit and tightening feel from a visible result during wear or after removal. A targeted firming cream brief should name the application area and appearance endpoint. Neither product name proves a change to fat, bone or body contour.
If the same serum also carries a tone-evening claim, include that wording in the market review and evidence plan. Our brightening product sourcing guide covers the related briefing decisions.
Serum, Cream and Patch: Verify the Finished Format
The same ingredient story can run across a line, but the three formats require separate development decisions. There is no useful universal ranking in which every cream holds more active than every hydrogel patch. Solvent system, material grade, processing, packaging and use conditions all matter.
On a small screen, swipe the table horizontally to read all columns.
| Format | What the sample must resolve | What to pin down in the specification |
|---|---|---|
| Peptide serum | The chosen grade in the proposed water, oil or emulsion system; changes in clarity, colour, odour, viscosity or visible particles. | Material and formula version, concentration basis, pH where applicable, fill size and performance of the selected pump or dropper. |
| Face or firming cream | Emulsion consistency, spread and finish with the complete ingredient combination, followed by agreed stability and pack checks. | Formula version, application area, container, dispensing requirements and acceptance criteria; avoid importing a serum result unchanged. |
| Hydrogel or collagen patch | Patch integrity, liquid distribution, fit, drying and removal behaviour in the proposed sachet or jar. | Substrate and liquid formula, patch weight or fill basis, pieces per pack, wear directions and whether an appearance endpoint is measured during wear or after removal. |
Caffeine illustrates why a percentage alone is insufficient. A proposal for "3% caffeine" cannot be accepted or rejected simply because the format is a patch: first identify what that percentage measures, then assess the actual formulation. Look for evidence of crystallisation, gel changes and packaging performance over the agreed conditions. A hydrogel eye patch and a body firming cream are separate development briefs, not proof that either can carry a specified caffeine level or deliver the same result.
Freeze-dried delivery is a separate brief. It adds questions about reconstitution, packaging and use after mixing; it does not remove the need to verify the resulting formulation. If that format is essential, use the dedicated freeze-dried serum sourcing guide rather than carrying over the assumptions for a ready-to-use serum.
What This Means for a Realistic Anti-Aging Line Plan
Work backwards from the product you intend to sell:
- Fix the destination and proposed claims. Identify the market review and evidence needed before approving wording.
- Fix the formats and use conditions. Define the serum, cream and patch separately, including the pack and application area.
- Allocate the development budget. Choose which SKU carries the main performance proposition and fund the evidence for that proposition.
- State the material and basis in writing. Link the quote, approved sample and formula version; document substitutions before approval.
For example, a line might pair a peptide serum with a richer cream and a targeted patch. They can share an ingredient story without claiming identical concentrations or results. For a fold-area patch, conformity, edge lift and residue are meaningful sample-comparison points; any softer-line appearance claim still needs suitable support. If you are deciding who supplies and develops the formula, OEM versus ODM helps define those responsibilities.
MOQ, Lead Time and Testing for Anti-Aging Products
The following are catalogue planning baselines. Confirm the selected SKU, packaging components and test scope in the quotation; a production interval is not the full time from first enquiry to market launch.
On a small screen, swipe the table horizontally to read all columns.
| Product type | MOQ baseline per SKU | Production planning range |
|---|---|---|
| Routine serum, essence-lotion and cream formats | From 3,000 units; confirm bottles, jars or tubes for the selected pack. | 35–60 days after approvals; confirm the product-specific range. |
| Collagen and hydrogel patches | 5,000–10,000 sheets; confirm sheets per pair, sachet, jar and retail pack. | 35–60 days after approvals; confirm the selected patch and pack. |
Confirm sample, formula, packaging, artwork and order approvals as schedule dependencies. Custom components, development rounds and pending evidence can affect timing. Do not assume that formal safety, stability, compatibility or claim studies are all included in the unit price or completed within the production window.
The EU cosmetic safety-report guidance addresses finished-product composition, stability, microbiological quality and packaging information. Agree the relevant work with the qualified assessor and testing providers for the actual product. A pleasant sample and a supplier ingredient dossier answer only part of that evidence requirement.
List the test owner, formula and pack version, conditions, acceptance criteria, report and cost for each agreed study. Accelerated observations and real-time stability data serve different purposes; neither should be described as a complete shelf-life guarantee without the supporting assessment. Our cosmetic stability testing guide explains the planning questions in more detail.
Questions Worth Asking Any Anti-Aging OEM
- Is that percentage supplied material or pure peptide? Request the manufacturer, exact grade and concentration basis behind it.
- Why was this level selected? Separate supplier guidance, relevant study conditions, formulation decisions and market requirements.
- What changes between the serum, cream and patch? Compare formula and pack versions, intended use and format-specific checks.
- Which result supports the claim? Identify the tested material or finished product, method, use period and endpoint.
- What is included in the price and schedule? Confirm the quote unit, per-SKU and component minimums, tests, reports and approvals.
Want a peptide quote that states the basis?
Send the target market, serum/cream/patch format, requested ingredient or reference sample, packaging and quantity per SKU. Ask for the material grade, concentration basis and testing scope to be stated in the proposal.
Frequently Asked Questions
Is a higher peptide percentage always better for anti-aging results?
No. First establish whether the number means a supplied blend or pure peptide, and identify the exact material. Even a comparable input level does not establish finished-product stability or results. Assess the evidence for the proposed formula and claim.
Why might a supplier recommend 0.04% adenosine?
Ask for the specific current rule, study or formulation rationale behind that figure. Do not treat it as a universal efficacy threshold or assume that changing it automatically improves performance or market access.
Can we claim our product rebuilds collagen if it contains peptides?
An ingredient name does not substantiate that claim. In the United States, FDA identifies claims to increase skin collagen production as affecting structure or function. Review the proposed wording and supporting evidence for the destination market before approving artwork.
Can one anti-aging formula be used across a serum, a cream and a patch?
The ingredient direction may be shared, but each finished format and package needs its own specification and appropriate verification. Do not assume a patch is a serum in a different pack, or that one format always permits a higher concentration.
How long does an anti-aging product take to produce?
The general planning range for routine serums, creams and patches is 35–60 days after approvals, subject to the selected SKU and packaging. Development, sampling, formal studies and shipping must be scoped separately; confirm what is included and when the quoted clock starts.
Can concentrations be adjusted for cost targets?
They can be considered during formulation review, alongside material grade, packaging and order size. Reassess the formula, evidence and proposed claim after a material change. A lower input cost is useful only if the revised product still meets the agreed specification.
Ready to Start Your Project?
Tell us your product requirements. Within 24 hours, our technical team will reply with a quotation or the questions needed to prepare one.